Qiagen said this week that it has promoted Hans Peter Fatscher to the position of vice president of sales, life sciences. He will be responsible for the life sciences sales organization in North America. He most recently served as director of global customer satisfaction for the company.
Former Illumina chief scientific officer David Barker has joined NextBio’s board of directors, NextBio said last week.
Before working at Illumina, Barker was chief science advisor at Amersham Biosciences, and served as vice president of research and business development at Molecular Dynamics.
Baker also worked in interdisciplinary neurobiological research at Harvard Medical School.
ClinXus, a western-Michigan non-profit promoting the region as a locale for pharmaceutical and medical device companies, this week named John Stark its executive director.
Stark formerly was a sales manager at Affymetrix. He is a native of the region and previously worked as a project manager for the Industrial Experimental and Manufacturing Co., and as an engineer for Motorola’s life sciences segment.
Epigenomics has proposed electing former Roche Diagnostics CEO Heino von Prondzynski to its supervisory board.
The vote would take place during Epigenomics’ next annual general meeting of shareholders. The company made the decision during a March 1 meeting of its supervisory board.
If elected, von Prondzynski would replace Zymogenetics CEO Bruce Carter.